Liquidia (LQDA) Net Margin Growth (1y) (2021 - 2026)
Analysis
Liquidia (LQDA) Net Margin Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.43 Bn | 625.67 Bn | 17.26 Bn | -146.00 |
| 2 | AbbVie | 442.46 Bn | 435.89 Bn | 12.70 Bn | 1,518.00 |
| 3 | Merck | 366.77 Bn | 359.63 Bn | 12.21 Bn | -3,607.00 |
| 4 | Novartis Ag | 266.59 Bn | 258.90 Bn | 11.24 Bn | -610.00 |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | -2,157.00 |
| 6 | Sanofi | 52.40 Bn | 45.02 Bn | 10.79 Bn | -3,647.00 |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | 166.00 |
| 9 | United Therapeutics | 21.53 Bn | 18.87 Bn | 683.80 Mn | 376.00 |
| 10 | Liquidia | 6.11 Bn | 5.82 Bn | 160.92 Mn | 51,402.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 51,402.00 |
| Mar 31, 2026 | 126,950.00 |
| Dec 31, 2025 | 133,601.00 |
| Sep 30, 2025 | 69,112.00 |
| Jun 30, 2025 | 31,298.00 |
| Mar 31, 2025 | -21,750.00 |
| Dec 31, 2024 | -71,437.00 |
| Sep 30, 2024 | -26,831.00 |
| Jun 30, 2024 | -29,212.00 |
| Mar 31, 2024 | -80,224.00 |
| Dec 31, 2023 | -48,394.00 |
| Sep 30, 2023 | -14,204.00 |
| Jun 30, 2023 | -25,025.00 |
| Mar 31, 2023 | 21,804.00 |
| Dec 31, 2022 | 23,777.00 |
| Sep 30, 2022 | -5,823.00 |
| Jun 30, 2022 | -4,704.00 |
| Mar 31, 2022 | -13,196.00 |
| Dec 31, 2021 | 181,529.00 |